Mutated EGFR-IN-1 |
| Catalog No.GC36666 |
L'EGFR-IN-1 muté (analogue de l'osimertinib) est un intermédiaire utile pour la conception d'inhibiteurs de l'EGFR muté, tels que L858R EGFR, le mutant d'activation de la suppression Exonl9 et le mutant de résistance T790M.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1421372-66-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Mutated EGFR-IN-1 is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant and T790M resistance mutant.IC50 value:Target: Mutated EGFR inhibitorMore information can be found in Patent WO 2013014448 A1.2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer. EGFRL858R EGFRExon 19 deletion/T790M EGFRT790M
[1]. Patent WO 2013014448 A1. 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer.
Average Rating: 5 (Based on Reviews and 5 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *